Novel Methods and Technologies for 21st-Century Clinical Trials A Review

被引:83
作者
Dorsey, E. Ray [1 ,2 ]
Venuto, Charles [1 ,2 ]
Venkataraman, Vinayak
Harris, Denzil A. [2 ]
Kieburtz, Karl [1 ,2 ,3 ]
机构
[1] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Clin & Translat Sci Inst, Rochester, NY 14642 USA
关键词
CONTINUAL REASSESSMENT METHOD; DRUG DEVELOPMENT; DISEASE PROGRESSION; HUNTINGTONS-DISEASE; LONG-TERM; FOLLOW-UP; TELEMEDICINE; OUTCOMES; DESIGN; PARTICIPANTS;
D O I
10.1001/jamaneurol.2014.4524
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE New technologies are rapidly reshaping health care. However, their effect on drug development to date generally has been limited. OBJECTIVES To evaluate disease modeling and simulation, alternative study design, novel objective measures, virtual research visits, and enhanced participant engagement and to examine their potential effects as methods and tools on clinical trials. EVIDENCE REVIEW We conducted a systematic search of relevant terms on PubMed (disease modeling and clinical trials; adaptive design, clinical trials, and neurology; Internet, clinical trials, and neurology; and telemedicine, clinical trials, and neurology), references of previous publications, and our files. The search encompassed articles published from January 1, 2000, through November 30, 2014, and produced 7976 articles, of which 22 were determined to be relevant and are included in this review. FINDINGS Few of these new methods and technologies have been applied to neurology clinical trials. Clinical outcomes, including cognitive and stroke outcomes, increasingly are captured remotely. Other therapeutic areas have successfully implemented many of these tools and technologies, including web-enabled clinical trials. CONCLUSIONS AND RELEVANCE Increased use of new tools and approaches in future clinical trials can enhance the design, improve the assessment, and engage participants in the evaluation of novel therapies for neurologic disorders.
引用
收藏
页码:582 / 588
页数:7
相关论文
共 65 条
[1]   The Past, Present, and Future of Telemedicine for Parkinson's Disease [J].
Achey, Meredith ;
Aldred, Jason L. ;
Aljehani, Noha ;
Bloem, Bastiaan R. ;
Biglan, Kevin M. ;
Chan, Piu ;
Cubo, Esther ;
Dorsey, E. Ray ;
Goetz, Christopher G. ;
Guttman, Mark ;
Hassan, Anhar ;
Khandhar, Suketu M. ;
Mari, Zoltan ;
Spindler, Meredith ;
Tanner, Caroline M. ;
van den Haak, Pieter ;
Walker, Richard ;
Wilkinson, Jayne R. .
MOVEMENT DISORDERS, 2014, 29 (07) :871-883
[2]   Estimating the cost of new drug development: Is it really $802 million? [J].
Adams, CP ;
Brantner, VV .
HEALTH AFFAIRS, 2006, 25 (02) :420-428
[3]  
Alfredo Caceres J, 2014, J Vasc Interv Neurol, V7, P34
[4]   Developing normalized strength scores for neuromuscular research [J].
Andres, Patricia L. ;
English, Robert ;
Mendoza, Michelle ;
Florence, Julaine ;
Malkus, Elizabeth ;
Schierbecker, Jeanine ;
Siener, Catherine ;
Malspeis, Susan ;
Schoenfeld, David A. ;
Munsat, Theodore L. ;
Cudkowicz, Merit E. .
MUSCLE & NERVE, 2013, 47 (02) :177-182
[5]  
[Anonymous], 1965, ELECTRONICS
[6]  
[Anonymous], 2014, ALL DISC HLTH AM SPE, V14
[7]  
[Anonymous], WALL STREET J
[8]  
[Anonymous], 2014, QUAL LIF NEUR DIS
[9]  
[Anonymous], 2012, WALL STREET J
[10]  
Berenson A, 2007, NY TIMES